Covered recipient · General Payments record
JOSE LUIS SUAREZ
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant Medical
General Payments · PY2021–2024
$1,392.79
- Reported across 79 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $282.54 | 15 |
| Education | $74.99 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Astellas Pharma US Inc | $74.99 | 1 |
| Novo Nordisk AS | $61.16 | 3 |
| Lilly USA, LLC | $38.20 | 2 |
| Phadia US Inc. | $35.35 | 2 |
| Acerta Pharma LLC | $34.12 | 2 |
| Merck Sharp & Dohme Corporation | $31.31 | 2 |
| ABBVIE INC. | $28.22 | 1 |
| Abbott Laboratories | $19.96 | 1 |
| Edwards Lifesciences Corporation | $18.46 | 1 |
| GlaxoSmithKline, LLC. | $15.76 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $19.96 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125096235 | CMS |
| ABBVIE INC. | $28.22 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108269500 | CMS |
| Astellas Pharma US Inc | $74.99 | 03/01/2024 | Education | Undisputed | 01/23/2026 | 1139504699 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.23 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104769006 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.89 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105848085 | CMS |
| Edwards Lifesciences Corporation | $18.46 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138858092 | CMS |
| GlaxoSmithKline, LLC. | $15.76 | 02/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115944282 | CMS |
| Lilly USA, LLC | $16.88 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135697462 | CMS |
| Lilly USA, LLC | $21.32 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135697464 | CMS |
| Merck Sharp & Dohme LLC | $17.21 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141921476 | CMS |
| Merck Sharp & Dohme LLC | $14.10 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141846091 | CMS |
| Novo Nordisk Inc | $23.73 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100575380 | CMS |
| Novo Nordisk Inc | $18.15 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100453058 | CMS |
| Novo Nordisk Inc | $19.28 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100344098 | CMS |
| Phadia US Inc. | $16.14 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1067580772 | CMS |
| Phadia US Inc. | $19.21 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1067580774 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.